Next-Gen Therapeutics for Fat Loss and Muscle Preservation: Emerging Targets and Strategies
The core content of this report is about the global Next-Gen therapeutics drugs for fat loss and muscle preservation. Starting from the leading antagonist of Activin (Activin) that targets the Activin-ActRII-ActRI pathway, the report elaborates on the basic information, mechanism of action, and therapy of the Activin-ActRII-ActRI pathway, and focuses on analyzing the key drugs in the ActRII pathway and other drugs for treating obesity and muscle loss syndrome. It presents a clear and comprehensive overview of the recent developments in the global research and development of new generation weight loss drugs for fat loss and muscle preservation.The summary section recommends some promising drugs and provides the reasons for the recommendations as well as possible risk factors.
